Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics (AUTL) Set to Announce Earnings on Tuesday
06:52am, Sunday, 01'st Mar 2020
Autolus Therapeutics (NASDAQ:AUTL) will be posting its quarterly earnings results before the market opens on Tuesday, March 3rd. Analysts expect Autolus Therapeutics to post earnings of ($0.71) per sh
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
07:52pm, Saturday, 29'th Feb 2020
Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
12:28pm, Friday, 28'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLa
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
02:36pm, Wednesday, 26'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen
Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference
12:00pm, Tuesday, 25'th Feb 2020
LONDON, Feb. 25, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3
12:00pm, Monday, 24'th Feb 2020
LONDON, Feb. 24, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and AquaBounty Technologies (AQB)
12:15pm, Tuesday, 18'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ionis Pharmaceuticals (IONS) and Autolus Therapeutics (AUTL)
02:54pm, Friday, 31'st Jan 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS) and Autolus Therapeutics (AUTL). Ionis
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals (IONS – Research
Autolus Therapeutics (AUTL) Gets a Buy Rating from H.C. Wainwright
12:11pm, Friday, 31'st Jan 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Autolus Therapeutics (AUTL) today and set a price target of $24.00. The company's
Autolus Therapeutics (AUTL) Gets a Buy Rating from H.C. Wainwright
12:11pm, Friday, 31'st Jan 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a
Autolus Therapeutics plc (AUTL) today announced additional data regarding its ongoing Phase 1/2 clinical trial of its next-generation programmed T cell therapy, AUTO3, to treat adults with relapsed/
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
12:12pm, Tuesday, 28'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmace
Autolus Announces Closing of Public Offering
09:00pm, Monday, 27'th Jan 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten
Autolus’ Chief Scientific Officer, Dr Martin Pulé, to give Keynote Lecture at the EHA-EBMT 2nd European CAR T Cell Meeting
12:00pm, Monday, 27'th Jan 2020
LONDON, Jan. 27, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces.
